Dendritic cell immunotherapy: clinical outcomes.
Dendritic cell immunotherapy: clinical outcomes.
复制标题
DOI：
10.1038/cti.2014.14
复制
发表时间：
2014-07
影响因子：
5.8
通讯作者：
中科院分区：
文献类型：
--
作者：
对这些自身抗原的耐受性加剧了肿瘤相关抗原在癌症免疫治疗研究中的使用。耐受性可以通过使用用自身抗原脉冲的离体单核细胞衍生的树突状细胞（DC）来打破。将肿瘤相关抗原直接靶向体内DC是一种替代且更简单的策略。鉴定DC上的细胞表面受体，并将抗原靶向DC受体，已经成为诱导针对癌症抗原的有效免疫应答的流行方法。许多年前，我们证明了在动物模型中使用碳水化合物甘露聚糖靶向巨噬细胞上的甘露糖受体到DC导致适当的免疫应答和肿瘤保护。我们进行了I期、I/II期和II期临床试验，证明了氧化甘露聚糖MUC 1在腺癌患者中的有效性。在这里，我们总结了DC靶向方法及其在人体临床试验中的疗效。
The use of tumour-associated antigens for cancer immunotherapy studies is exacerbated by tolerance to these self-antigens. Tolerance may be broken by using ex vivo monocyte-derived dendritic cells (DCs) pulsed with self-antigens. Targeting tumour-associated antigens directly to DCs in vivo is an alternative and simpler strategy. The identification of cell surface receptors on DCs, and targeting antigens to DC receptors, has become a popular approach for inducing effective immune responses against cancer antigens. Many years ago, we demonstrated that targeting the mannose receptor on macrophages using the carbohydrate mannan to DCs led to appropriate immune responses and tumour protection in animal models. We conducted Phase I, I/II and II, clinical trials demonstrating the effectiveness of oxidised mannan-MUC1 in patients with adenocarcinomas. Here we summarise DC targeting approaches and their efficacy in human clinical trials.